口服地屈孕酮与口服地屈孕酮联合微粒化阴道黄体酮在排卵性冻融胚胎移植周期黄体期支持中的比较
本回顾性队列研究纳入2011年1月至2023年2月期间首次接受排卵方案冻融胚胎移植的22,868例患者,比较口服地屈孕酮(DYD)单药与DYD联合微粒化阴道黄体酮(MVP)进行黄体期支持(LPS)的疗效与安全性。倾向性评分匹配(PSM)后每组各6153例,两组临床妊娠率(51.8% vs 52.2%,P=0.626)、活产率(42.8% vs 43.2%,P=0.623)及流产率(P=0.637)均无显著差异,新生儿性别、出生体重及出生缺陷亦无显著差异(P>0.05)。结论认为在排卵性冻融胚胎移植周期中,口服DYD单药用于黄体期支持在妊娠及新生儿结局方面与DYD+MVP相当。
要点
- PSM后口服DYD单药组与DYD+MVP组临床妊娠率分别为51.8%和52.2%,无显著差异(P=0.626)。
- 两组活产率分别为42.8%和43.2%,无显著差异(P=0.623);流产率亦无显著差异(P=0.637)。
- 新生儿性别、出生体重及出生缺陷在两组间均无显著差异(P>0.05)。
核心结论
- 在排卵性冻融胚胎移植周期中,口服DYD单药用于黄体期支持在妊娠及新生儿结局方面与DYD+MVP相当。
研究设计与样本
- 本回顾性队列研究纳入2011年1月至2023年2月期间首次接受排卵方案冻融胚胎移植的22,868例患者。
- 患者根据黄体期支持方案分为口服DYD单药组和DYD+MVP组,经倾向性评分匹配(PSM)后每组各6153例。
- 进一步按子宫内膜准备方案(自然周期、来曲唑或人绝经期促性腺激素)进行分层分析。
- 采用逻辑回归及基于母亲年龄的分层分析对PSM前结果进行验证。
主要发现
- PSM后,口服DYD组与DYD+MVP组的临床妊娠率分别为51.8%和52.2%,无显著差异(P=0.626)。
- 两组活产率分别为42.8%和43.2%,无显著差异(P=0.623);流产率亦无显著差异(P=0.637)。
- 上述结果在各子宫内膜准备方案中均得到验证。
- 两组新生儿性别、出生体重及出生缺陷均无显著差异(P>0.05)。
- 回归分析显示黄体期支持方案对临床妊娠率无影响(P=0.672);分层分析显示在年龄<35岁和≥35岁患者中,黄体期支持方案对临床妊娠率、活产率或流产率均无影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is oral dydrogesterone (DYD) alone as effective as DYD + micronized vaginal progesterone (MVP) for luteal phase support (LPS) in ovulatory frozen-thawed embryo transfer (FET) cycles? DESIGN: This retrospective cohort study included 22,868 patients undergoing their first FET cycles using an ovulatory protocol between January 2011 and February 2023. Patients were classified into two cohorts according to LPS protocol: oral DYD alone or DYD + MVP. After propensity score matching (PSM), pregnancy and neonatal outcomes were compared to determine the efficacy and safety of oral DYD alone. Further stratification was made to observe the effect of oral DYD alone for each endometrial preparation regimen (natural, letrozole or human menopausal gonadotrophin). Logistic regression and stratified analysis based on maternal age further confirmed the results before PSM. RESULTS: After PSM, there were 6153 patients in the oral DYD group and 6153 patients in the DYD + MVP group. No significant differences in the clinical pregnancy rate (CPR) (51.8% versus 52.2%, P = 0.626), live birth rate (LBR) (42.8% versus 43.2%, P = 0.623), miscarriage rate (P = 0.637) and other pregnancy outcomes were observed between the two cohorts. These results were reconfirmed for each endometrial preparation protocol. No significant differences in newborn sex, birth weight or birth defects were found between the two cohorts (P > 0.05). Regression analysis showed no influence of LPS protocol on CPR (P = 0.672). Stratified analysis showed no impact of LPS protocol on CPR, LBR or miscarriage rate in patients aged <35 years and patients aged ≥35 years. CONCLUSIONS: Oral DYD alone is comparable to DYD + MVP for LPS in ovulatory FET cycles in terms of pregnancy and neonatal outcomes.
引用
- Jiang X, Li W, Chen X, et al. Oral dydrogesterone versus oral dydrogesterone plus micronized vaginal progesterone for luteal phase support in ovulatory frozen-thawed embryo transfers. Reprod Biomed Online. 2025. PMID: 40413849. doi:10.1016/j.rbmo.2025.104844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。